Treatment of actinic cheilitis with imiquimod 5% and a retractor on the lower lip

clinical and histological outcomes in 5 patients

Christopher McDonald, Sean Laverick, Colin J. Fleming, Sharon J. White

    Research output: Contribution to journalArticle

    17 Citations (Scopus)

    Abstract

    Imiquimod 5% (Aldara (TM), 3M Healthcare Ltd.) is a topically applied immune response modifier used in the treatment of superficial basal cell carcinoma, actinic keratosis, and genital warts. We reviewed the casenotes of 5 patients with histologically confirmed dysplastic lower lips who had been treated with topical imiquimod.

    Each patient was provided with a specially designed lower lip retractor to prevent spread of the cream. Treatment was stopped after 6 weeks or if an acute inflammatory reaction developed. The lower lip was biopsied 4 weeks later, and histologically the dysplastic changes had been reversed in all 5 patients. The lip retractor was well-tolerated, and prevented spread of the cream. Imiquimod 5% cream offers an alternative method to manage dysplastic lips. Our lip retractor is a simple and cost-effective method of isolating the lower lip and allowing application of topical agents. The method could equally well be used for agents other than imiquimod. (C) 2009 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

    Original languageEnglish
    Pages (from-to)473-476
    Number of pages4
    JournalBritish Journal of Oral and Maxillofacial Surgery
    Volume48
    Issue number6
    DOIs
    Publication statusPublished - Sep 2010

    Keywords

    • Actinic cheilitis
    • Dysplasia
    • Imiquimod
    • Lip retractor
    • Lip shave
    • BASAL-CELL CARCINOMA
    • CREAM
    • MELANOMA
    • THERAPY
    • MUCOSA

    Cite this

    @article{6c5404e2be964dc79d0c88ec95701109,
    title = "Treatment of actinic cheilitis with imiquimod 5{\%} and a retractor on the lower lip: clinical and histological outcomes in 5 patients",
    abstract = "Imiquimod 5{\%} (Aldara (TM), 3M Healthcare Ltd.) is a topically applied immune response modifier used in the treatment of superficial basal cell carcinoma, actinic keratosis, and genital warts. We reviewed the casenotes of 5 patients with histologically confirmed dysplastic lower lips who had been treated with topical imiquimod.Each patient was provided with a specially designed lower lip retractor to prevent spread of the cream. Treatment was stopped after 6 weeks or if an acute inflammatory reaction developed. The lower lip was biopsied 4 weeks later, and histologically the dysplastic changes had been reversed in all 5 patients. The lip retractor was well-tolerated, and prevented spread of the cream. Imiquimod 5{\%} cream offers an alternative method to manage dysplastic lips. Our lip retractor is a simple and cost-effective method of isolating the lower lip and allowing application of topical agents. The method could equally well be used for agents other than imiquimod. (C) 2009 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.",
    keywords = "Actinic cheilitis, Dysplasia, Imiquimod, Lip retractor, Lip shave, BASAL-CELL CARCINOMA, CREAM, MELANOMA, THERAPY, MUCOSA",
    author = "Christopher McDonald and Sean Laverick and Fleming, {Colin J.} and White, {Sharon J.}",
    year = "2010",
    month = "9",
    doi = "10.1016/j.bjoms.2009.08.024",
    language = "English",
    volume = "48",
    pages = "473--476",
    journal = "British Journal of Oral and Maxillofacial Surgery",
    issn = "0266-4356",
    publisher = "Elsevier",
    number = "6",

    }

    Treatment of actinic cheilitis with imiquimod 5% and a retractor on the lower lip : clinical and histological outcomes in 5 patients. / McDonald, Christopher; Laverick, Sean; Fleming, Colin J.; White, Sharon J.

    In: British Journal of Oral and Maxillofacial Surgery, Vol. 48, No. 6, 09.2010, p. 473-476.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Treatment of actinic cheilitis with imiquimod 5% and a retractor on the lower lip

    T2 - clinical and histological outcomes in 5 patients

    AU - McDonald, Christopher

    AU - Laverick, Sean

    AU - Fleming, Colin J.

    AU - White, Sharon J.

    PY - 2010/9

    Y1 - 2010/9

    N2 - Imiquimod 5% (Aldara (TM), 3M Healthcare Ltd.) is a topically applied immune response modifier used in the treatment of superficial basal cell carcinoma, actinic keratosis, and genital warts. We reviewed the casenotes of 5 patients with histologically confirmed dysplastic lower lips who had been treated with topical imiquimod.Each patient was provided with a specially designed lower lip retractor to prevent spread of the cream. Treatment was stopped after 6 weeks or if an acute inflammatory reaction developed. The lower lip was biopsied 4 weeks later, and histologically the dysplastic changes had been reversed in all 5 patients. The lip retractor was well-tolerated, and prevented spread of the cream. Imiquimod 5% cream offers an alternative method to manage dysplastic lips. Our lip retractor is a simple and cost-effective method of isolating the lower lip and allowing application of topical agents. The method could equally well be used for agents other than imiquimod. (C) 2009 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

    AB - Imiquimod 5% (Aldara (TM), 3M Healthcare Ltd.) is a topically applied immune response modifier used in the treatment of superficial basal cell carcinoma, actinic keratosis, and genital warts. We reviewed the casenotes of 5 patients with histologically confirmed dysplastic lower lips who had been treated with topical imiquimod.Each patient was provided with a specially designed lower lip retractor to prevent spread of the cream. Treatment was stopped after 6 weeks or if an acute inflammatory reaction developed. The lower lip was biopsied 4 weeks later, and histologically the dysplastic changes had been reversed in all 5 patients. The lip retractor was well-tolerated, and prevented spread of the cream. Imiquimod 5% cream offers an alternative method to manage dysplastic lips. Our lip retractor is a simple and cost-effective method of isolating the lower lip and allowing application of topical agents. The method could equally well be used for agents other than imiquimod. (C) 2009 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

    KW - Actinic cheilitis

    KW - Dysplasia

    KW - Imiquimod

    KW - Lip retractor

    KW - Lip shave

    KW - BASAL-CELL CARCINOMA

    KW - CREAM

    KW - MELANOMA

    KW - THERAPY

    KW - MUCOSA

    U2 - 10.1016/j.bjoms.2009.08.024

    DO - 10.1016/j.bjoms.2009.08.024

    M3 - Article

    VL - 48

    SP - 473

    EP - 476

    JO - British Journal of Oral and Maxillofacial Surgery

    JF - British Journal of Oral and Maxillofacial Surgery

    SN - 0266-4356

    IS - 6

    ER -